Subcutaneous tendon rupture of extensor tendons on bilateral wrists associated with calcium pyrophosphate dihydrate crystal deposition disease

References

• Sauve L, Kapandji M. Nouvelle technique de traitement chirurgi-cal des luxation rechidivantes isolee de l'extremite inferieur du cubitus. J Chir 1936;47:589–94.
   Google Scholar
• McCarty DJ, Kohn NN, Faires JS. The significance of calcium phosphate crystals in the synovial fluid of arthritic patients: the "pseudogout syndrome". I. Clinical aspects. Ann Intern Med 1962;56: 711–37.
   Google Scholar
• McCarty DJ. Calcium pyrophosphate dehydrate crystal deposition disease. Arthritis Rheum 1976;19:275–85.
   PubMed Web of Science ®Google Scholar
• Resnick D, Niwayama G, Goergen TG, Utsinger PD, Shapiro FtF, Haselwood DH, Wiesner KB. Clinical, radiographic and patho-logic abnormalities in calcium pyrophosphate deposition disease (CPPD): pseudogout. Radiology 1977;122:1–15.
   Google Scholar
• Resnick D, Niwayama G. Capital instability in rheumatoid arthritis and calcium pyrophosphatevdeposition disease. Pathogenesis and roentgen appearance. Ann Rheum Dis 1977;36:311–8.
   PubMed Web of Science ®Google Scholar
• Smathers RL, Stellin CB, Kears TE. The destructive wrist arthrop-athy of pseudogout. Skelet Radiol 1982;7:255–8.
   PubMedGoogle Scholar
• Blinder Al, Sheppard MN, Parice E. Extensor tendon rupture related to calcium pyrophosphate crystal deposition disease. Br J Ftheumatol 1989;28:251–3.
   Google Scholar
• Van Linthoudt D, Gabay C, Otto H. Extensor tendon rupture related to calcium pyrophosphate crystal deposition disease. Br J Ftheumatol 1989;28:552–3.
   Google Scholar
• Zenklusen C, Alnot JY, Bocquet L, Kahn MF. Case report. Exten-sor tendon rupture related to destructive change of the inferior radio-ulnar joint: a newly recognized manifestation of chondrocal-cinosis. J Orthop Rheumatol 1989;2:235–40.
   Google Scholar
• Jones A, Barton N, Pattrick M, Doherty M. Tophaceous pyrophos-phate deposition with extensor tendon rupture. Br J Ftheumatol 1992;31:421–3.
   PubMedGoogle Scholar
• Taniguchi Y, Yoshida M, Tamaki T. Subcutaneous extensor tendon rupture associated with calcium pyrophosphate dehydrate crystal deposition disease of wrist. J Hand Surg [Br] 1997;22:386–7.
   Google Scholar
• Waguri-Nagaya Y, Kokubo Y, Sekiya I, Otsuka T, Shiomi I, Shimizu H, et al. Extensor tendon rupture related to calcium pyro-phosphate crystal deposition disease. Ftheumatol Int 2002;21: 243–6.
   Google Scholar
• Terkeltaub R, Zachariae C, Santoro D, Martin J, Peveri P, Matsu-shima K. Monocyte-derived neutrophil chemotactic factor/inter-leukin-8 is a potential mediator of crystal-induced inflammation. Arthritis Rheum 1991;34: 894–903.
   Google Scholar
• di Giovine FS, Malawista SE, Thornton E, Duff GW. Urate crys-tals stimulate production of tumor necrosis factor alpha from human blood monocytes and synovial cells. Cytokine mFtNA and protein kinetics, and cellular distribution. J Clin Invest 1991;87: 1375–81.
   PubMed Web of Science ®Google Scholar
• Liu-Bryan R, Liote E Monosodium urate and calcium pyrophos-phate dihydrate (CPPD) crystals, inflammation, and cellular sig-naling. Joint Bone Spine 2005;72:295–302.
   PubMed Web of Science ®Google Scholar
• Liu R, O'Connell M, Johnson K, Pritzker K, Mackman N, Terkel-taub R. Extracellular signal-regulated kinase l/extracellular signal- regulated kinase 2 mitogen-activated protein kinase signaling and activation of activator protein 1 and nuclear factor kappaB tran-scription factors play central roles in interleukin-8 expression stimulated by monosodium urate monohydrate and calcium pyro-phosphate crystals in monocytic cells. Arthritis Rheum 2000;43: 1145–55.
   PubMedGoogle Scholar
• Liu R, Liote F, Rose DM, Merz D, Terkeltaub R. Proline-rich tyrosine kinase 2 and Src kinase signaling transduce monosodium urate crystal-induced nitric oxide production and matrix metallo-proteinase 3 expression in chondrocytes. Arthritis Rheum 2004; 50:247–58.
   Google Scholar
• Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594–602.
   Google Scholar
• Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932–9.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleis-chmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340:253–9.
   Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50: 2264–72.
   PubMed Web of Science ®Google Scholar
• Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis con-trolled trial (IMPACT). Arthritis Rheum 2005;52:1227–36.
   PubMed Web of Science ®Google Scholar
• Hirose J, Ryan LM, Masuda I. Up-regulated expression of carti-lage intermediate-layer protein and ANK in articular hyaline car-tilage from patients with calcium pyrophosphate dihydrate crystal deposition disease. Arthritis Rheum 2002;46:3218–29.
   Google Scholar
• Darrach W. Anterior dislocation of the head of the ulna. Ann Surg 1912;56:802–3.
   Google Scholar